First Targeted Bladder Cancer Treatment Shows Promising Phase I Results
Posted:
In a potential win for targeted therapy in bladder cancer, Johnson & Johnson announced results from a Phase I study of erdafitinib (Erda-iDRS) in patients with the intermediate-risk non-muscle-invasive form of the disease.
GIANT Health is delighted to welcome XR Therapeutics to GIANT Health 2026 as part of the NHS Innovation Accelerator (NIA) Pavilion, where they will showcase how immersive technology is helping transform mental health care across the NHS.
Mental health services…
GIANT Health is pleased to welcome Psyomics to GIANT Health 2026 as part of the NHS Innovation Accelerator (NIA) Pavilion, where they will showcase their innovative approach to improving mental health services through better information, earlier understanding and more informed…
Attendees
Sponsors and Exhibitors
Contact us